A new FDA-approved treatment for Hunter syndrome (MPS II) is giving families hope, but it’s not a cure. We explore how close researchers may be to a cure, including promising gene therapy clinical trials, and what experts say still needs long-term study.

00:00 intro
00:45 How this story began: a mom reaches out about newly approved Avlayah.
01:03 Why it matters: therapy designed to cross the blood-brain barrier.
01:20 The emotional center: two moms bond while navigating the same diagnosis.
02:23 Hunter syndrome (MPS II) explained: missing enzyme, sugar buildup, organ/brain damage.
03:40 How the “next-gen” enzyme replacement works using an enzyme transport vehicle.
04:16 Early impact: reported behavioral/physical improvements and infusion-center support.
05:36 “Not a cure” → what a cure could look like; intro to gene therapy.
06:23 London trial spotlight: one-time ex vivo gene therapy; early (anecdotal) improvements. https://www.gosh.nhs.uk/news/gosh-manufactures-new-gene-therapy-for-rare-condition/
08:01 U.S. clinical trial in New Jersey: timelines and what’s still unknown. https://clinicaltrials.gov/study/NCT07236606
08:48 Physician Assistant Laura Buch: long-term durability, dosing questions, and rare-disease trial limits.
10:03 Advocacy + how to find trials on ClinicalTrials.gov; closing thoughts.
https://clinicaltrials.gov/study/NCT03566043